GenMark Diagnostics Inc. (NASDAQ:GNMK)’s share price traded up 2.3% during trading on Friday . The company traded as high as $9.74 and last traded at $9.70, with a volume of 61,022 shares traded. The stock had previously closed at $9.48.

Several brokerages have commented on GNMK. Canaccord Genuity reiterated a “buy” rating and set a $8.00 price target on shares of GenMark Diagnostics in a report on Wednesday, May 4th. Needham & Company LLC reiterated a “buy” rating on shares of GenMark Diagnostics in a report on Wednesday, May 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $8.43.

The firm’s market capitalization is $415.04 million. The firm’s 50 day moving average is $8.79 and its 200-day moving average is $6.49.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. The firm earned $11.06 million during the quarter, compared to analyst estimates of $10.67 million. During the same quarter in the previous year, the business earned ($0.24) EPS. GenMark Diagnostics’s quarterly revenue was up 9.5% compared to the same quarter last year. Equities analysts anticipate that GenMark Diagnostics Inc. will post ($1.23) EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. I.G. Investment Management LTD. boosted its stake in GenMark Diagnostics by 0.7% in the fourth quarter. I.G. Investment Management LTD. now owns 134,589 shares of the company’s stock valued at $1,044,000 after buying an additional 978 shares during the last quarter. Morgan Stanley boosted its stake in GenMark Diagnostics by 10,433.5% in the fourth quarter. Morgan Stanley now owns 1,338,286 shares of the company’s stock valued at $10,385,000 after buying an additional 1,325,581 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in GenMark Diagnostics by 7.3% in the fourth quarter. Jennison Associates LLC now owns 3,144,434 shares of the company’s stock valued at $24,401,000 after buying an additional 214,822 shares during the last quarter.

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.